Clinical Trial Update: Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine with or without imatinib mesylate in metastatic or unresectable kidney cancer; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Imatinib (imatinib)

Snippet

Sponsor: University of Medicine and Dentistry of New Jersey | Conditions: Kidney Cancer | Phase 2 | Status: TERMINATED